Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cartesian Therapeutics, Inc.RNAC · Entity 6015 | Director | November 13, 2023 | November 15, 2023 |
| Viridian Therapeutics, Inc.\DEVRDN · Entity 4316 | Director · Chief Executive Officer | April 12, 2023 | April 12, 2023 |
| Zentalis Pharmaceuticals, Inc.ZNTL · Entity 5772 | Director | June 16, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cartesian Therapeutics, Inc.
Report date November 13, 2023 · Filed November 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.10 · Expires 2029-06-13 | Direct | 0 |
Reported balance
After 2023-11-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-11-13 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: This option, which provided for vesting in thirty-six (36) substantially equal monthly installments over three years following the date of grant on June 14, 2019, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2030-06-18 | Direct | 0 |
Reported balance
After 2023-11-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-11-13 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: This option, which provided for vesting in full on June 17, 2021, was canceled in the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.01 · Expires 2031-03-29 | Direct | 0 |
Reported balance
After 2023-11-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-11-13 · Disposition to issuer · Disposed 40,000 · Balance 0 F3: This option, which provided for vesting in full on March 30, 2022, was canceled in the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.31 · Expires 2032-01-02 | Direct | 0 |
Reported balance
After 2023-11-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-11-13 · Disposition to issuer · Disposed 40,000 · Balance 0 F4: This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.13 · Expires 2033-01-01 | Direct | 0 |
Reported balance
After 2023-11-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-11-13 · Disposition to issuer · Disposed 87,500 · Balance 0 F5: This option, which provided for vesting in full on January 2, 2024, was canceled in the Merger in exchange for a cash payment of $81,375, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: This option, which provided for vesting in thirty-six (36) substantially equal monthly installments over three years following the date of grant on June 14, 2019, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc.
F2: This option, which provided for vesting in full on June 17, 2021, was canceled in the Merger.
F3: This option, which provided for vesting in full on March 30, 2022, was canceled in the Merger.
F4: This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger.
F5: This option, which provided for vesting in full on January 2, 2024, was canceled in the Merger in exchange for a cash payment of $81,375, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger.
Viridian Therapeutics, Inc.\DE
Report date April 12, 2023 · Filed April 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 259,500 |
Reported balance
After 2023-04-12 transaction · row 1
1 source rowRow 1 · 2023-04-12 · Purchase · Acquired 4,000 · Balance 259,500 |
Zentalis Pharmaceuticals, Inc.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 395,895 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 57,100 · Balance 395,895 F1: Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2027 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2027 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.
Past disclosures · reporting ended (5)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AMAG PHARMACEUTICALS, INC.
Report date November 16, 2020 · Filed November 17, 2020
Section 16 reporting ended · disclosed 2020-11-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-11-16 · Disposition to issuer · Disposed 1,000,000 · Balance 0 F2: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time").
F2: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.
Cascadian Therapeutics, Inc.
Report date March 09, 2018 · Filed March 13, 2018
Section 16 reporting ended · disclosed 2018-03-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-03-09 transaction · row 1
1 source rowRow 1 · 2018-03-09 · Other · Disposed 56,787 · Balance 0 F1: Shares of Common Stock tendered in the tender offer launched by Valley Acquisition Sub, Inc. on February 8, 2018 pursuant to that certain Agreement and Plan of Merger, dated January 30, 2018, among Seattle Genetics, Inc., Valley Acquisition Sub, Inc., and Cascadian Therapeutics, Inc. (the "Merger Agreement"), to acquire all of the outstanding shares of common stock of Cascadian Therapeutics, Inc., par value $0.0001 per share, at a purchase price of $10.00 per share ("Offer Price"), net to the seller in cash, without interest and less any required withholding taxes. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.08 · Expires 2026-04-04 | Direct | 0 |
Reported balance
After 2018-03-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-03-09 · Disposition to issuer · Disposed 474,810 · Balance 0 F3: Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $1,386,445.20, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option. F2: 25% of the shares subject to the option vest on the first anniversary of the grant date of April 4, 2016, and the remainder vest monthly thereafter for 36 months. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.64 · Expires 2027-01-11 | Direct | 0 |
Reported balance
After 2018-03-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-03-09 · Disposition to issuer · Disposed 190,000 · Balance 0 F5: Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $1,018,400.00, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option. F4: 25% of the shares subject to the option vest on the first anniversary of the grant date of January 11, 2017, and the remainder vest monthly thereafter for 36 months. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.99 · Expires 2027-09-18 | Direct | 0 |
Reported balance
After 2018-03-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-03-09 · Disposition to issuer · Disposed 60,000 · Balance 0 F7: Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $360,600.00, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option. F6: 25% of the shares subject to the option vest on the first anniversary of the grant date of September 18, 2017, and the remainder vest monthly thereafter for 36 months. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-03-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-03-09 · Disposition to issuer · Disposed 42,000 · Balance 0 F8: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $420,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F9: The restricted stock units were granted on January 11, 2017 and 25% of the shares vest on each anniversary of the grant date for four years. F10: The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-03-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-03-09 · Disposition to issuer · Disposed 15,500 · Balance 0 F11: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $155,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F12: The restricted stock units were granted on September 18, 2017 and 25% of the shares vest on each anniversary of the grant date for four years. F10: The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-03-09 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-03-09 · Disposition to issuer · Disposed 6,300 · Balance 0 F13: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $63,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F14: The restricted stock units were granted on November 10, 2017 and 25% of the shares vest on each anniversary of the grant date for four years. F10: The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-03-09 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-03-09 · Disposition to issuer · Disposed 250,000 · Balance 0 F15: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $2,500,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F16: The restricted stock units were granted on January 31, 2018 and 25% of the shares vest on each anniversary of the grant date for four years. F10: The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of Common Stock tendered in the tender offer launched by Valley Acquisition Sub, Inc. on February 8, 2018 pursuant to that certain Agreement and Plan of Merger, dated January 30, 2018, among Seattle Genetics, Inc., Valley Acquisition Sub, Inc., and Cascadian Therapeutics, Inc. (the "Merger Agreement"), to acquire all of the outstanding shares of common stock of Cascadian Therapeutics, Inc., par value $0.0001 per share, at a purchase price of $10.00 per share ("Offer Price"), net to the seller in cash, without interest and less any required withholding taxes.
F2: 25% of the shares subject to the option vest on the first anniversary of the grant date of April 4, 2016, and the remainder vest monthly thereafter for 36 months.
F3: Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $1,386,445.20, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option.
F4: 25% of the shares subject to the option vest on the first anniversary of the grant date of January 11, 2017, and the remainder vest monthly thereafter for 36 months.
F5: Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $1,018,400.00, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option.
F6: 25% of the shares subject to the option vest on the first anniversary of the grant date of September 18, 2017, and the remainder vest monthly thereafter for 36 months.
F7: Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $360,600.00, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option.
F8: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $420,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price.
F9: The restricted stock units were granted on January 11, 2017 and 25% of the shares vest on each anniversary of the grant date for four years.
F10: The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service.
F11: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $155,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price.
F12: The restricted stock units were granted on September 18, 2017 and 25% of the shares vest on each anniversary of the grant date for four years.
F13: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $63,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price.
F14: The restricted stock units were granted on November 10, 2017 and 25% of the shares vest on each anniversary of the grant date for four years.
F15: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $2,500,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price.
F16: The restricted stock units were granted on January 31, 2018 and 25% of the shares vest on each anniversary of the grant date for four years.
DYNAVAX TECHNOLOGIES CORP
Report date February 10, 2026 · Filed February 10, 2026
Section 16 reporting ended · disclosed 2026-02-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-02-10 transaction · row 1
1 source rowRow 1 · 2026-02-10 · Other · Disposed 3,800 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Price. |
| Common Stock - Restricted Stock UnitsSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-02-10 transaction · row 2
1 source rowRow 2 · 2026-02-10 · Disposition to issuer · Disposed 31,204 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") award that was outstanding as of immediately prior to the Effective Time held by the Reporting Person, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such RSU award immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.55 | Direct | 0 |
Reported balance
After 2026-02-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-10 · Disposition to issuer · Disposed 45,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F5: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.68 | Direct | 0 |
Reported balance
After 2026-02-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-10 · Disposition to issuer · Disposed 16,875 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F5: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.20 | Direct | 0 |
Reported balance
After 2026-02-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-10 · Disposition to issuer · Disposed 22,500 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F5: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.85 | Direct | 0 |
Reported balance
After 2026-02-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-10 · Disposition to issuer · Disposed 22,500 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F5: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.18 | Direct | 0 |
Reported balance
After 2026-02-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-10 · Disposition to issuer · Disposed 28,500 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time"). F5: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Purchaser").
F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for $15.50 per share (the "Offer Price"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the "Effective Time").
F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Price.
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") award that was outstanding as of immediately prior to the Effective Time held by the Reporting Person, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares issuable in settlement of such RSU award immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price.
F5: Pursuant to the terms of the Merger Agreement, (i) each stock option that was outstanding as of immediately prior to the Effective Time held by the Reporting Person became fully vested immediately prior to the Effective Time, and (ii) at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to (i) the number of shares subject to such stock option immediately prior to the Effective Time, without regard to vesting, multiplied by (ii) the excess of the Offer Price over the exercise price per share of such stock option.
Harpoon Therapeutics, Inc.
Report date March 11, 2024 · Filed March 11, 2024
Section 16 reporting ended · disclosed 2024-03-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-03-11 transaction · row 1
1 source rowRow 1 · 2024-03-11 · Disposition to issuer · Disposed 22,665 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F2: Includes 19,900 restricted stock units ("RSUs") which are subject to rounding as a result of the 1:10 reverse stock split effective September 1, 2023. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.0001 per share ("Common Stock"). F3: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding RSU was cancelled and automatically converted into the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (i) the Common Stock Merger Consideration (as defined below) payable with respect to such RSU multiplied by (ii) the total number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, with the number of shares of Company Common Stock subject to any such Company RSU that vests based on the achievement of performance goals determined in accordance with the applicable award agreement. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding share of Common Stock was cancelled and automatically converted into the right to receive $23.00 in cash, without interest (the "Common Stock Merger Consideration"). |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.10 | Direct | 0 |
Reported balance
After 2024-03-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-03-11 · Disposition to issuer · Disposed 2,033 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F6: (Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.66 | Direct | 0 |
Reported balance
After 2024-03-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-11 · Disposition to issuer · Disposed 4,600 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the F6: (Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger").
F2: Includes 19,900 restricted stock units ("RSUs") which are subject to rounding as a result of the 1:10 reverse stock split effective September 1, 2023. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.0001 per share ("Common Stock").
F3: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding RSU was cancelled and automatically converted into the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (i) the Common Stock Merger Consideration (as defined below) payable with respect to such RSU multiplied by (ii) the total number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, with the number of shares of Company Common Stock subject to any such Company RSU that vests based on the achievement of performance goals determined in accordance with the applicable award agreement.
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding share of Common Stock was cancelled and automatically converted into the right to receive $23.00 in cash, without interest (the "Common Stock Merger Consideration").
F5: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a "Stock Option"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an "In the Money Option") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the
F6: (Continued from footnote 5) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof.
Trillium Therapeutics Inc.
Report date November 17, 2021 · Filed November 19, 2021
Section 16 reporting ended · disclosed 2021-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.51 · Expires 2031-05-03 | Direct | 0 |
Reported balance
After 2021-11-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-11-17 · Disposition to issuer · Disposed 67,000 · Balance 0 F1: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 19, 2020 Filed Jun 23, 2020 20:47 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001453687-20-000077 · wf-form4_159294520886842.xml · derivative · entry 1 Myers Scott Dunseth · CIK 0001356256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-06-18 F1 · derivative.exercise_date: The option vests in full on the earlier of June 19, 2021 or the day immediately prior to the company's 2021 annual meeting of stockholders. Read SEC document |
| May 28, 2020 Filed Jun 2, 2020 01:50 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | GrantDirector Stock Option (Right to Buy) · Derivative | 10,167 | $0.00 Strike: $20.59 | $0.00 |
DisclosureSEC source: 0001209191-20-033323 · doc4.xml · derivative · entry 1 Myers Scott Dunseth · CIK 0001356256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,167 Underlying: Common Stock · 10,167 shares Expires 2030-05-27 F1 · derivative.exercise_date: The stock option will fully vest and become exercisable on May 28, 2021, subject to the continuous service of the Reporting Person with the Issuer on such date. Read SEC document |
| April 28, 2020 Filed Apr 30, 2020 17:02 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantStock Option (Right to Buy) · Derivative | 1,000,000 | Not disclosed Strike: $8.20 | Not disclosed |
DisclosureSEC source: 0000792977-20-000037 · wf-form4_158828054244692.xml · derivative · entry 1 Myers Scott Dunseth · CIK 0001356256 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2030-04-28 F2 · price: Not applicable. F1 · derivative.exercise_date: This option vests and becomes exercisable in four equal annual installments commencing on April 28, 2021. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 22:29 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantWarrants · Derivative | 19,704 | $0.13 Strike: $1.46 | $2,463.00 |
DisclosureSEC source: 0001104659-19-076220 · a4.xml · derivative · entry 2 Myers Scott Dunseth · CIK 0001356256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,704 Underlying: Common Stock · 19,704 shares Expires 2024-12-23 Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 22:29 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantCommon Stock | 39,409 | $1.46 | $57,537.14 |
DisclosureSEC source: 0001104659-19-076220 · a4.xml · nonDerivative · entry 1 Myers Scott Dunseth · CIK 0001356256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,845 Read SEC document |
| August 20, 2019 Filed Aug 20, 2019 20:32 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantCommon Stock | 41,436 | $1.81 | $74,999.16 |
DisclosureSEC source: 0001453687-19-000124 · wf-form4_156633313666723.xml · nonDerivative · entry 1 Myers Scott Dunseth · CIK 0001356256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,436 Read SEC document |
| June 14, 2019 Filed Jun 18, 2019 20:21 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001453687-19-000071 · wf-form4_156088926892404.xml · derivative · entry 1 Myers Scott Dunseth · CIK 0001356256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-06-13 F1 · derivative.exercise_date: The option vests in thirty-six (36) substantially equal monthly installments over three years following the date of grant. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 21:30 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | GrantDirector Stock Option (Right to Buy) · Derivative | 10,167 | $0.00 Strike: $11.84 | $0.00 |
DisclosureSEC source: 0001209191-19-034848 · doc4.xml · derivative · entry 1 Myers Scott Dunseth · CIK 0001356256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,167 Underlying: Common Stock · 10,167 shares Expires 2029-06-02 F1 · derivative.exercise_date: The stock option will fully vest and become exercisable on June 3, 2020, subject to the continuous service of the Reporting Person with the Issuer on such date. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 18:07 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | Disposition to issuerRestricted Stock Units · Derivative | 250,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-007300 · doc4.xml · derivative · entry 8 Myers Scott Dunseth · CIK 0001356256 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires not disclosed F15 · derivative.exercise_price: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $2,500,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F15 · price: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $2,500,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F16 · derivative.exercise_date: The restricted stock units were granted on January 31, 2018 and 25% of the shares vest on each anniversary of the grant date for four years. F10 · derivative.expiration_date: The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 18:07 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | Disposition to issuerRestricted Stock Units · Derivative | 6,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-007300 · doc4.xml · derivative · entry 7 Myers Scott Dunseth · CIK 0001356256 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,300 shares Expires not disclosed F13 · derivative.exercise_price: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $63,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F13 · price: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $63,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F14 · derivative.exercise_date: The restricted stock units were granted on November 10, 2017 and 25% of the shares vest on each anniversary of the grant date for four years. F10 · derivative.expiration_date: The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 18:07 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | Disposition to issuerRestricted Stock Units · Derivative | 15,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-007300 · doc4.xml · derivative · entry 6 Myers Scott Dunseth · CIK 0001356256 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,500 shares Expires not disclosed F11 · derivative.exercise_price: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $155,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F11 · price: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $155,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F12 · derivative.exercise_date: The restricted stock units were granted on September 18, 2017 and 25% of the shares vest on each anniversary of the grant date for four years. F10 · derivative.expiration_date: The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 18:07 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | Disposition to issuerRestricted Stock Units · Derivative | 42,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-007300 · doc4.xml · derivative · entry 5 Myers Scott Dunseth · CIK 0001356256 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,000 shares Expires not disclosed F8 · derivative.exercise_price: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $420,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F8 · price: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $420,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F9 · derivative.exercise_date: The restricted stock units were granted on January 11, 2017 and 25% of the shares vest on each anniversary of the grant date for four years. F10 · derivative.expiration_date: The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 18:07 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | Disposition to issuerStock Option (Right to buy) · Derivative | 60,000 | Not disclosed Strike: $3.99 | Not disclosed |
DisclosureSEC source: 0000899243-18-007300 · doc4.xml · derivative · entry 4 Myers Scott Dunseth · CIK 0001356256 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2027-09-18 F7 · price: Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $360,600.00, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option. F6 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary of the grant date of September 18, 2017, and the remainder vest monthly thereafter for 36 months. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 18:07 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | Disposition to issuerStock Option (Right to buy) · Derivative | 190,000 | Not disclosed Strike: $4.64 | Not disclosed |
DisclosureSEC source: 0000899243-18-007300 · doc4.xml · derivative · entry 3 Myers Scott Dunseth · CIK 0001356256 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 190,000 shares Expires 2027-01-11 F5 · price: Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $1,018,400.00, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option. F4 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary of the grant date of January 11, 2017, and the remainder vest monthly thereafter for 36 months. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 18:07 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | Disposition to issuerStock Option (Right to buy) · Derivative | 474,810 | Not disclosed Strike: $7.08 | Not disclosed |
DisclosureSEC source: 0000899243-18-007300 · doc4.xml · derivative · entry 2 Myers Scott Dunseth · CIK 0001356256 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 474,810 shares Expires 2026-04-04 F3 · price: Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $1,386,445.20, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option. F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary of the grant date of April 4, 2016, and the remainder vest monthly thereafter for 36 months. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 18:07 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | OtherCommon Stock | 56,787 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-007300 · doc4.xml · nonDerivative · entry 1 Myers Scott Dunseth · CIK 0001356256 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Shares of Common Stock tendered in the tender offer launched by Valley Acquisition Sub, Inc. on February 8, 2018 pursuant to that certain Agreement and Plan of Merger, dated January 30, 2018, among Seattle Genetics, Inc., Valley Acquisition Sub, Inc., and Cascadian Therapeutics, Inc. (the "Merger Agreement"), to acquire all of the outstanding shares of common stock of Cascadian Therapeutics, Inc., par value $0.0001 per share, at a purchase price of $10.00 per share ("Offer Price"), net to the seller in cash, without interest and less any required withholding taxes. Read SEC document |
| February 01, 2018 Filed Feb 2, 2018 17:54 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | GrantRestricted Share Unit (RSU) · Derivative | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-007135 · doc4.xml · derivative · entry 1 Myers Scott Dunseth · CIK 0001356256 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2022-02-01 F1 · derivative.exercise_price: Approximately 70% of each RSU represents a contingent right to receive approximately 0.70 share of the issuer's Common Stock upon vesting and approximately 30% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate the holder's satisfaction of U.S. federal tax obligations in connection with the vesting of the RSUs. F2 · derivative.exercise_date: Twenty-five percent of the shares underlying the RSU vest on each of February 1, 2019, February 1, 2020, February 1, 2021 and February 1, 2022, subject to the holder's continued employment with the issuer on each vesting date. Read SEC document |
| January 11, 2018 Filed Jan 16, 2018 17:26 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | Exercise / conversionRestricted Share Unit (RSU) · Derivative | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-003646 · doc4.xml · derivative · entry 3 Myers Scott Dunseth · CIK 0001356256 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 10,500 shares Expires 2027-01-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Approximately 67% of each RSU represents a contingent right to receive approximately 0.67 share of the issuer's Common Stock upon vesting and approximately 33% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate the holder's satisfaction of U.S. federal tax obligations in connection with the vesting of the RSUs. F3 · derivative.exercise_date: Twenty-five percent of the shares underlying the RSU vest on each of January 11, 2018, January 11, 2019, January 11, 2020 and January 11, 2021, subject to the holder's continued employment with the issuer on each vesting date. Read SEC document |
| January 11, 2018 Filed Jan 16, 2018 17:26 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | Tax withholdingCommon Stock | 3,429 | $3.92 | $13,441.68 |
DisclosureSEC source: 0001209191-18-003646 · doc4.xml · nonDerivative · entry 2 Myers Scott Dunseth · CIK 0001356256 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,787 F1 · shares: 3,429 shares of the restricted share unit ("RSU") grant, which represent approximately 33% of the shares underlying the RSU grant that vested on January 11, 2018, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on January 11, 2018 to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person. F1 · price: 3,429 shares of the restricted share unit ("RSU") grant, which represent approximately 33% of the shares underlying the RSU grant that vested on January 11, 2018, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on January 11, 2018 to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person. Read SEC document |
| January 11, 2018 Filed Jan 16, 2018 17:26 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | Exercise / conversionCommon Stock | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-003646 · doc4.xml · nonDerivative · entry 1 Myers Scott Dunseth · CIK 0001356256 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,216 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2017 Filed Nov 13, 2017 20:00 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | GrantRestricted Share Unit (RSU) · Derivative | 6,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-060478 · doc4.xml · derivative · entry 1 Myers Scott Dunseth · CIK 0001356256 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,300 Underlying: Common Stock · 6,300 shares Expires 2021-09-18 F1 · derivative.exercise_price: Approximately 67% of each RSU represents a contingent right to receive approximately 0.67 share of the issuer's Common Stock upon vesting and approximately 33% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate the holder's satisfaction of U.S. federal tax obligations in connection with the vesting of the RSUs. F2 · derivative.exercise_date: Twenty-five percent of the shares underlying the RSU vest on each of September 18, 2018, September 18, 2019, September 18, 2020 and September 18, 2021, subject to the holder's continued employment with the issuer on each vesting date. Read SEC document |
| September 18, 2017 Filed Sep 20, 2017 21:07 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | GrantRestricted Share Unit (RSU) · Derivative | 15,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-053535 · doc4.xml · derivative · entry 2 Myers Scott Dunseth · CIK 0001356256 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 Underlying: Common Stock · 15,500 shares Expires 2021-09-18 F2 · derivative.exercise_price: Approximately 67% of each RSU represents a contingent right to receive approximately 0.67 share of the issuer's Common Stock upon vesting and approximately 33% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate the holder's satisfaction of U.S. federal tax obligations in connection with the vesting of the RSUs. F3 · derivative.exercise_date: Twenty-five percent of the shares underlying the RSU vest on each of September 18, 2018, September 18, 2019, September 18, 2020 and September 18, 2021, subject to the holder's continued employment with the issuer on each vesting date. Read SEC document |
| September 18, 2017 Filed Sep 20, 2017 21:07 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001209191-17-053535 · doc4.xml · derivative · entry 1 Myers Scott Dunseth · CIK 0001356256 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2027-09-18 F1 · derivative.exercise_date: The option vests and is exercisable at the rate of 1/4th of the total shares on September 18, 2018 and then 1/48th of the total shares vest and are exercisable monthly thereafter, with 100% vested and exercisable on September 18, 2021, subject to the holder's continued employment with the issuer on each vesting date. Read SEC document |
| August 11, 2017 Filed Aug 14, 2017 17:12 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | PurchaseCommon Stock | 5,500 | $3.74 | $20,542.50 |
DisclosureSEC source: 0001209191-17-048790 · doc4.xml · nonDerivative · entry 1 Myers Scott Dunseth · CIK 0001356256 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,716 F1 · price: The reported price in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $3.728 to $3.76 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. Read SEC document |
| May 12, 2017 Filed May 16, 2017 17:43 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | PurchaseCommon Stock | 2,800 | $4.00 | $11,191.60 |
DisclosureSEC source: 0001209191-17-032832 · doc4.xml · nonDerivative · entry 1 Myers Scott Dunseth · CIK 0001356256 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,216 F1 · price: The reported price in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $3.9969 to $3.9975 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 17:39 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | PurchaseCommon Stock | 2,000 | $4.11 | $8,228.60 |
DisclosureSEC source: 0001209191-17-025174 · doc4.xml · nonDerivative · entry 1 Myers Scott Dunseth · CIK 0001356256 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,416 Read SEC document |
| March 20, 2017 Filed Mar 21, 2017 20:09 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | PurchaseCommon Stock | 1,000 | $3.93 | $3,927.10 |
DisclosureSEC source: 0001209191-17-022141 · doc4.xml · nonDerivative · entry 1 Myers Scott Dunseth · CIK 0001356256 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,416 Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 16:55 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | PurchaseCommon Stock | 20,500 | $3.76 | $77,039.00 |
DisclosureSEC source: 0001209191-17-006410 · doc4.xml · nonDerivative · entry 1 Myers Scott Dunseth · CIK 0001356256 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,416 F1 · price: The reported price in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $3.695 to $3.8435 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Effective as of November 29, 2016, the issuer effected a 6-for-1 reverse split of its common stock. The number of shares above reflects the reverse stock split. Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 19:48 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | GrantRestricted Share Unit (RSU) · Derivative | 42,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-003757 · doc4.xml · derivative · entry 2 Myers Scott Dunseth · CIK 0001356256 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2021-01-11 F2 · derivative.exercise_price: Approximately 67% of each RSU represents a contingent right to receive approximately 0.67 share of the issuer's Common Stock upon vesting and approximately 33% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate the holder's satisfaction of U.S. federal tax obligations in connection with the vesting of the RSUs. F3 · derivative.exercise_date: Twenty-five percent of the shares underlying the RSU vest on each of January 11, 2018, January 11, 2019, January 11, 2020 and January 11, 2021, subject to the holder's continued employment with the issuer on each vesting date. Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 19:48 UTC | Cascadian Therapeutics, Inc. CASC · Entity 168341 | GrantStock Option (right to buy) · Derivative | 190,000 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001209191-17-003757 · doc4.xml · derivative · entry 1 Myers Scott Dunseth · CIK 0001356256 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 190,000 shares Expires 2027-01-11 F1 · derivative.exercise_date: The option vests and is exercisable at the rate of 1/4th of the total shares on January 11, 2018 and then 1/48th of the total shares vest and are exercisable monthly thereafter, with 100% vested and exercisable on January 11, 2021, subject to the holder's continued employment with the issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.